Development pipeline

Indatuximab Ravtansine (BT-062)

Indatuximab Ravtansine (BT-062) is an immune conjugate, consisting of a monoclonal antibody to which a highly effective cytotoxic maytansien derivative (DM4) is coupled. The immune conjugate technology, developed by ImmunoGen, Inc, is used for toxin conjugation. The antibody is directed against the CD138 receptor, which is over-expressed on multiple myeloma cells and on other cells of various types of cancer: solid tumors.

After the conjugate is absorbed into the target cell, DM4 is released and exerts its cytotoxic activity so that the tumor cell is killed. This combination of high effectiveness and specificity with low systemic toxicity distinguishes BT-062 from most therapies currently used in oncology.

Press releases

New data from Biotest's monoclonal antibody-drug-conjug...

03.05.2018,

New data from Biotest's monoclonal antibody-drug-conjugate (ADC) BT-062 in the therapy of solid tumors- Good tolerability and signs of efficacy in phase I/IIa clinical study- Very good effectiveness w ... [More]

ImmunoGen has elected not to exercise its late stage co...

24.03.2017,

ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062) - License agreement with ImmunoGen will continueDreieich, 2 ... [More]

Encouraging data of Indatuximab Ravtansine (BT-062) in ...

06.12.2016,

Encouraging data of Indatuximab Ravtansine (BT-062) in combination therapy in advanced Multiple Myeloma- New data from BT-062 in combination therapy presented at 58th annual conference of the American ... [More]

Biotest increases revenues in first half year 2015 by 8...

11.08.2015,

Biotest increases revenues in first half year 2015 by 8.9%- Clinical development of BT-061 will be discontinued- Capacity expansion at headquarter Dreieich on schedule- Board of management confirms EB ... [More]

Encouraging Efficacy of Indatuximab Ravtansine (BT-062)...

09.12.2014,

Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone- New data from combination therapy study presented at 56th annual confere ... [More]

Further preclinical studies emphasise the potential of ...

24.10.2014,

Further preclinical studies emphasise the potential of Indatuximab Ravtansine (BT-062) in solid tumours - Antibody-drug conjugate shows high efficacy in an animal model in the treatment of bladder, br ... [More]

Biotest continues to show a sales increase

07.05.2014,

PRESS RELEASEBiotest continues to show a sales increase - Sales at EUR 122.2 million (+2.9%) - Progress in CapEx program "Biotest Next Level" - Positive development in R&D projectsDreieich,7 May 2014 ... [More]

Biotest AG initiates clinical study with Indatuximab Ra...

27.03.2014,

Biotest AG initiates clinical study with Indatuximab Ravtansine (BT-062) in solid tumors- First patient treated in phase I/IIa study (no. 989) in patients with triple-negative metastatic breast cancer ... [More]

Clinical Study with Indatuximab Ravtansine (BT-062) in ...

10.12.2013,

Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone. - Efficacy and tolerability ... [More]

Biotest Group with double digit EBIT growth

13.08.2012,

PRESS RELEASEBiotest Group with double digit EBIT growth - Sales increase to EUR 220.2 mio. - EBIT increase by 14.5% to EUR 22.9 EUR mio. - Management confirms guidance 2012Dreieich, 13 August 2012. ... [More]

Biotest AG starts combination therapy study with BT-06...

16.07.2012,

Biotest AG starts combination therapy study with BT-062 in multiple myeloma - Antibody-drug conjugate BT-062 continues to show good tolerability in monotherapy - First patient treated in phase I/IIa c ... [More]

Biotest Group reports substantially higher EBIT

10.05.2012,

Biotest Group reports substantially higher EBIT - EBIT up 14.3% at EUR 10.4 million - Sales increased to EUR 107.7 million - Management Board confirms forecastDreieich, 10 May 2012. The Biotest Group ... [More]

BT-062 demonstrates rapid and complete tumor eradicatio...

22.03.2012,

PRESS RELEASEBT-062 demonstrates rapid and complete tumor eradication in preclinical studies - Pronounced anti-tumor activity against aggressive solid tumors, e.g. human breast, pancreas, bladder and ... [More]

Biotest reached an all-time high Profit after Tax

22.03.2012,

Biotest reached an all-time high Profit after Tax - Profit after tax of the Biotest Group (Continuing Operations and Discontinued Operation) at EUR48.1 million represents an increase of 21.8% vs. the ... [More]

Clinical development of BT-062 in multiple myeloma expa...

12.12.2011,

Clinical development of BT-062 in multiple myeloma expands into combination therapy  Efficacy and tolerability data from monotherapy studies 969 and 975 presented at 53rd annual conference of th ... [More]

Biotest: Significant Increase in Profit after Tax

10.11.2011,

Biotest: Significant Increase in Profit after Tax - Increase of Profit after tax by 31.1% (Continuing and Discontinued Operations) - Profit after tax contribution of EUR 22 million from sale of ... [More]

Sales increase despite difficult market environment

22.03.2011,

22.03.2011 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services ... [More]

Clinical and pre-clinical data emphasise the potential ...

06.12.2010,

Language: English Company: Biotest AG Landsteinerstraße 5 ... [More]

Biotest: Pre-clinical studies demonstrate high efficacy...

17.11.2010,

Biotest: Pre-clinical studies demonstrate high efficacy of BT-062 in solid tumours  Immunoconjugate induces complete remission of human solid tumours in mouse models  High anti-tumour activity ... [More]

Biotest experiences sales growth

08.11.2010,

Biotest experiences sales growth  Sales after nine months 3.5% above the previous year  Performance continues to be affected by the difficult market environment  Board of Management confirms ... [More]

Conference dates

03.12.2016 – 06.12.2016 | San Diego

Publications

preview

ASH 2014 American Society of Hematology (06.12.2014 – 09.12.2014, San Francisco)
PDF, 398.98 kB
[ Download ]

preview

World ADC Weltkongress Antibody Drug Conjugates (26.10.2014 – 29.10.2014, San Diego)
PDF, 834.64 kB
[ Download ]

preview

ASH 2013 American Society of Hematology (06.12.2013 - 10.12.2013, New Orleans)
PDF, 41.61 kB
[ Download ]

preview

ASH 2012 American Society of Hematology, 8. - 11. Dez. 2012, Atlanta (USA)
PDF, 387.58 kB
[ Download ]

preview

Tassone et al.: Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 2004 Dec 1;104(12):3688-96
[ Link ]

preview

Ikeda et al.: The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.Clin Cancer Res. 2009, Jun 15;15(12):4028-37
[ Link ]

Clinical trials

Title

Indication

Status

 
Indatuximab Ravtansine (Study 983) Multiple myeloma Study ongoing

BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma

Link clinicaltrials.gov
 
Indatuximab Ravtansine (Study 975) Multiple myeloma Study completed

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

 
Indatuximab Ravtansine (Study 969) Multiple myeloma Study completed

Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

 
Indatuximab Ravtansine* (Study 989) Solid tumors Study ongoing

An open-label, twostage Phase I/IIa dose escalation study of BT062 in metastatic triple receptor-negative breast cancer and in metastatic transitional cell carcinoma of the urinary bladder

Link clinicaltrialsregister.eu